- Home
- IBIO vs LGVN Comparison
IBIO vs LGVN Comparison
Compare IBIO & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- LGVN
- Stock Information
- Founded
- IBIO 2008
- LGVN 2014
- Country
- IBIO United States
- LGVN United States
- Employees
- IBIO N/A
- LGVN N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- IBIO Health Care
- LGVN Health Care
- Exchange
- IBIO Nasdaq
- LGVN Nasdaq
- Market Cap
- IBIO 16.4M
- LGVN 16.4M
- IPO Year
- IBIO N/A
- LGVN 2021
- Fundamental
- Price
- IBIO $0.87
- LGVN $0.89
- Analyst Decision
- IBIO Strong Buy
- LGVN Strong Buy
- Analyst Count
- IBIO 2
- LGVN 2
- Target Price
- IBIO $5.50
- LGVN $6.50
- AVG Volume (30 Days)
- IBIO 376.3K
- LGVN 399.0K
- Earning Date
- IBIO 11-11-2025
- LGVN 11-11-2025
- Dividend Yield
- IBIO N/A
- LGVN N/A
- EPS Growth
- IBIO N/A
- LGVN N/A
- EPS
- IBIO N/A
- LGVN N/A
- Revenue
- IBIO $400,000.00
- LGVN $2,073,000.00
- Revenue This Year
- IBIO N/A
- LGVN N/A
- Revenue Next Year
- IBIO N/A
- LGVN N/A
- P/E Ratio
- IBIO N/A
- LGVN N/A
- Revenue Growth
- IBIO 77.78
- LGVN 68.67
- 52 Week Low
- IBIO $0.56
- LGVN $0.63
- 52 Week High
- IBIO $6.89
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- IBIO 60.39
- LGVN 48.25
- Support Level
- IBIO $0.78
- LGVN $0.73
- Resistance Level
- IBIO $0.86
- LGVN $0.82
- Average True Range (ATR)
- IBIO 0.04
- LGVN 0.03
- MACD
- IBIO 0.00
- LGVN 0.02
- Stochastic Oscillator
- IBIO 95.55
- LGVN 94.35
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.